Table 5. The effects of eleven KYQG samples on IL-1β, TNF-α, IL-8, and IL-6 production.
| Group | Dose | IL-1β (pg/mL) | TNF-α (pg/mL) | IL-8 (pg/mL) | IL-6 (pg/mL) |
|---|---|---|---|---|---|
| Control | Medium | 11.63 ± 0.93 | 1.20 ± 0.02 | 215.11 ± 9.52 | 2.14 ± 0.05 |
| Model | Medium | 20.28 ± 2.12** | 1.74 ± 0.03** | 272.93 ± 12.80** | 3.14 ± 0.11** |
| NP | 10 μg/mL | 10.64 ± 0.91## | 1.23 ± 0.09## | 239.81 ± 14.04## | 2.76 ± 0.16 |
| Dex | 1 μM | 15.21 ± 1.15## | 1.37 ± 0.02## | 230.85 ± 3.72## | 2.60 ± 0.27# |
| S1 | 55.6 μg/mL | 18.92 ± 0.35 | 1.15 ± 0.10## | 289.76 ± 3.37 | 2.37 ± 0.14## |
| S2 | 55.6 μg/mL | 18.06 ± 2.73 | 1.64 ± 0.19 | 265.53 ± 13.31 | 2.53 ± 0.19## |
| S3 | 55.6 μg/mL | 15.83 ± 1.21## | 1.58 ± 0.12 | 261.08 ± 14.86 | 2.87 ± 0.34 |
| S4 | 55.6 μg/mL | 14.72 ± 1.57## | 1.22 ± 0.07## | 341.33 ± 14.79 | 2.53 ± 0.16## |
| S5 | 55.6 μg/mL | 15.96 ± 0.87## | 1.50 ± 0.12# | 250.25 ± 6.24# | 2.64 ± 0.19# |
| S6 | 55.6 μg/mL | 12.62 ± 1.15## | 1.12 ± 0.14## | 237.00 ± 10.85## | 2.53 ± 0.16## |
| S7 | 55.6 μg/mL | 17.44 ± 0.93 | 1.93 ± 0.11 | 252.69 ± 9.45 | 2.79 ± 0.30 |
| S8 | 55.6 μg/mL | 13.11 ± 1.40## | 1.77 ± 0.02 | 341.92 ± 7.89 | 2.14 ± 0.14## |
| S9 | 55.6 μg/mL | 14.23 ± 1.15## | 1.77 ± 0.08 | 288.33 ± 8.85 | 2.56 ± 0.14## |
| S10 | 55.6 μg/mL | 14.35 ± 1.39## | 1.89 ± 0.11 | 259.30 ± 2.87 | 2.60 ± 0.22# |
| S11 | 55.6 μg/mL | 13.61 ± 1.32## | 1.40 ± 0.15## | 279.84 ± 15.76 | 2.11 ± 0.14## |
Data are presented as the mean ± SD, n = 3.
S1-S11 represented the eleven KYQG samples.
Dex: Dexamethasone; NP: Niuhuangjiedu Pian; KYQG: Kouyanqing Granule.
Control group and model group received the same volume of RPMI-1640 medium for the treatment.
*P < 0.05 and **P < 0.01 vs. control group, #P < 0.05 and ##P < 0.01 vs. model group.